slc38a11 Antibody

What is SLC38A11 and what cellular functions has research attributed to it?

SLC38A11 (also known as AVT2, FLJ39822, or MGC150450) is a putative sodium-dependent amino acid/proton antiporter belonging to the solute carrier family 38 member 11 . It is considered a putative sodium-coupled neutral amino acid transporter, though it remains largely classified as an "orphan family member" with incompletely characterized functions .

What are the key characteristics of commercially available SLC38A11 antibodies?

Currently available SLC38A11 antibodies share several important characteristics:

These antibodies are affinity-isolated and undergo validation through various methods including IHC tissue arrays and protein arrays for specificity confirmation .

What detection methods are optimal for SLC38A11 using antibody-based approaches?

Immunohistochemistry (IHC) represents the primary validated application for SLC38A11 antibodies. When conducting IHC experiments:

• Optimal dilution range: 1:20-1:50 (though dilution optimization is recommended for each specific application)

• Validated for paraffin-embedded tissues, particularly human skeletal muscle

• For Western blot applications, SLC38A11 typically appears as a band at approximately 46 kDa (compared to its predicted molecular weight of 49.6 kDa in mouse)

The selection of detection method should align with research objectives, with immunohistochemistry currently representing the most reliable approach based on supplier validations .

How does nutritional stress through amino acid starvation impact SLC38A11 expression patterns?

Research examining amino acid starvation's effects on SLC38A11 has yielded nuanced results. In a study using the immortalized hypothalamic cell line N25/2, Western blot analysis showed variable responses of SLC38A11 protein expression to complete amino acid starvation after 5 hours:

This contrasts with the significant transcriptional upregulation observed for other SLC38 family members (particularly SLC38A1, SLC38A2, and SLC38A7) under identical starvation conditions . The data suggests SLC38A11 may be regulated differently than other family members, potentially through post-transcriptional mechanisms.

The contradiction between individual sample responses highlights the complexity of SLC38A11 regulation and the need for robust experimental design with sufficient biological replicates when studying its response to metabolic stressors.

What experimental design considerations are crucial when using SLC38A11 antibodies in Western blot applications?

When designing Western blot experiments to detect SLC38A11:

• Expected molecular weight: Approximately 46 kDa in experimental detection, compared to the predicted 49.6 kDa (453 amino acids, NP_796048)

• Loading controls: β-actin has been validated as an appropriate normalization control

• Sample preparation considerations:

  • Ensure complete lysis to extract membrane proteins

  • Avoid excessive heat during sample preparation that might cause protein aggregation

  • Consider detergent selection appropriate for membrane proteins

• Antibody validation strategy:

  • Include positive controls when possible

  • Consider using multiple antibodies targeting different epitopes

  • Validate signal specificity through knockdown/knockout controls if feasible

• Quantification approach:

  • Normalize to housekeeping proteins

  • Consider technical triplicates to address variability observed in amino acid starvation studies

How can researchers effectively investigate SLC38A11 in relation to other SLC38 family members?

Research examining relationships between SLC38A11 and other family members requires careful experimental design:

• Expression profiling strategy:

  • qPCR analysis can detect all 11 SLC38 family members (SLC38A1-11) simultaneously

  • Note that SLC38A4 and SLC38A11 typically show lower expression levels (CT>35), requiring careful interpretation

  • Consider multiplex approaches for protein detection when examining multiple family members

• Differential regulation patterns:

  • Unlike SLC38A1, SLC38A2, and SLC38A7 (which show significant upregulation during amino acid starvation), SLC38A11 protein levels remain relatively stable

  • This suggests distinct regulatory mechanisms that should be accounted for in experimental design

• Cell type considerations:

  • Expression levels vary significantly between cell types

  • In primary embryonic cortex cells, SLC38A11 shows lower expression compared to immortalized hypothalamic cells

• Heat map analysis approach:

  • Use heat map visualization to compare expression changes across multiple family members simultaneously

  • Include appropriate time points (1h, 2h, 3h, 5h, 16h) to capture temporal dynamics

What are the most effective validation strategies for confirming SLC38A11 antibody specificity?

Given SLC38A11's status as a less characterized transporter, rigorous validation is essential:

• Multi-platform validation approach:

  • Combine Western blot detection with immunohistochemistry results

  • Evaluate consistency of staining patterns across multiple tissues

  • Compare results from antibodies targeting different epitopes when available

• Cross-reactivity assessment:

  • Test against recombinant protein fragments from multiple SLC38 family members

  • Evaluate using protein arrays (some commercial antibodies are validated against 364 human recombinant protein fragments)

• Tissue microarray validation:

  • Commercial Prestige Antibodies undergo validation on tissue arrays containing 44 normal human tissues and 20 common cancer types

  • Consider similar comprehensive approaches when developing custom antibodies

• Functional validation:

  • Correlate antibody detection with mRNA expression data

  • Consider knockout/knockdown models when feasible

  • Verify expected molecular weight (approximately 46 kDa vs. predicted 49.6 kDa)

How should researchers interpret contradictory results when studying SLC38A11 regulation under metabolic stress conditions?

The variability in SLC38A11 responses to amino acid starvation highlights important considerations:

• Statistical approach for inconsistent results:

  • In published studies, SLC38A11 showed downregulation in two samples but upregulation in one sample after starvation

  • When combined, these changes were not statistically significant (p = 0.4108)

  • This emphasizes the need for adequate biological replicates and appropriate statistical analysis

• Temporal dynamics considerations:

  • Consider examining multiple time points, as SLC38 family members show time-dependent regulation

  • Some family members show significant changes only at specific time points (5h or 16h)

• Cell type-specific regulation:

  • Results from immortalized cell lines may differ from primary cells

  • SLC38A11 had low mRNA expression in primary cortex cells but was detectable in hypothalamic cell lines

• Total vs. specific amino acid deprivation:

  • Different experimental designs use either complete amino acid starvation or deprivation of specific amino acids

  • These approaches may yield different results for SLC38A11 regulation

• Transcriptional vs. post-transcriptional regulation:

  • Compare mRNA and protein level changes

  • The lack of correlation between transcriptional and protein-level changes suggests complex regulatory mechanisms

What protocol modifications improve detection sensitivity when working with low-abundance SLC38A11?

Given SLC38A11's relatively low expression levels, sensitivity optimization is crucial:

• Signal amplification strategies for IHC:

  • Consider tyramide signal amplification for low-abundance targets

  • Optimize antigen retrieval conditions (heat-induced epitope retrieval at pH 9.0 often improves results)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Reduce washing stringency while maintaining specificity

• Western blot sensitivity enhancements:

  • Increase protein loading (50-100 μg total protein)

  • Consider extended transfer times for membrane proteins

  • Use high-sensitivity chemiluminescent substrates

  • Optimize blocking conditions (5% BSA often performs better than milk for phospho-specific antibodies)

• Sample enrichment approaches:

  • Consider subcellular fractionation to enrich membrane proteins

  • Use immunoprecipitation to concentrate target protein before analysis

  • Select tissues with known expression (skeletal muscle has been validated)

What controls are essential when validating novel findings about SLC38A11 function?

Rigorous experimental controls are necessary when investigating this understudied transporter:

• Antibody specificity controls:

  • Peptide competition assays using the immunogen peptide (AISLGPHIPKTEDAWVFAKPNAIQ)

  • Positive control tissues with validated expression

  • Negative controls (secondary antibody only)

• Expression manipulation controls:

  • siRNA or shRNA knockdown validation

  • Overexpression with tagged constructs

  • Comparison with mRNA expression data

• Experimental condition controls:

  • Include multiple time points to capture temporal dynamics

  • Use biological replicates (minimum of 3, given observed variability)

  • Include related SLC38 family members as comparative controls

• Data analysis controls:

  • Multiple housekeeping genes/proteins for normalization

  • Appropriate statistical testing with corrections for multiple comparisons

  • Blinded analysis of imaging data

How can SLC38A11 research contribute to understanding neurological disorders?

SLC38A11 research has potential implications for neurological disorders:

• Amino acid sensing pathway involvement:

  • SLC38 family members participate in amino acid sensing and signaling in the brain

  • Disruptions in these pathways may contribute to neurological conditions

• Expression pattern significance:

  • SLC38A11 shows differential regulation compared to other family members

  • This unique regulation pattern may indicate specialized functions in specific neural circuits

• Potential research directions:

  • Investigate SLC38A11 expression in neurodevelopmental disorder models

  • Examine relationships between SLC38A11 and mTOR signaling pathways

  • Explore potential roles in amino acid-responsive neurological conditions

What emerging techniques could advance SLC38A11 functional characterization?

Several cutting-edge approaches could enhance our understanding of SLC38A11:

• CRISPR-based methodologies:

  • Generate knockout/knockin models to study function

  • Use CRISPRi/CRISPRa to modulate expression levels

  • Employ CRISPR screens to identify functional relationships

• Advanced imaging approaches:

  • Super-resolution microscopy to determine subcellular localization

  • Live-cell imaging with fluorescently tagged constructs

  • Multiplexed imaging to examine co-localization with other transporters

• Transport assays:

  • Electrophysiological approaches to characterize transport properties

  • Radiolabeled substrate uptake studies

  • Fluorescent substrate analogs for real-time transport monitoring

• Systems biology integration:

  • Proteomics to identify interaction partners

  • Metabolomics to assess impacts on amino acid homeostasis

  • Transcriptomics to identify co-regulated genes